Get the Stockscreener App
5.40
4.09%
-0.23
Ensysce Biosciences Inc stock is traded at $5.40, with a volume of 15,039.
It is down -4.09% in the last 24 hours and down -32.50% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$5.63
Open:
$5.56
24h Volume:
15,039
Relative Volume:
0.15
Market Cap:
$7.05M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-1.794
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
-6.90%
1M Performance:
-32.50%
6M Performance:
-11.29%
1Y Performance:
-61.29%
1-Day Range:
$5.25
$5.635
1-Week Range:
$5.25
$6.14
52-Week Range:
$2.118
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
5.40 | 7.05M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire
Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire
How To Trade (ENSC) - Stock Traders Daily
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit - ACCESS Newswire
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - ACCESS Newswire
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection - ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - NEWSnet
Ensysce reports overdose protection in drug trial - Investing.com
Ensysce's PF614-MPAR Shows Breakthrough Overdose Protection in Phase 1b Opioid Trial - StockTitan
Biotech Steals The Show Following $14 Million Grant Announcement - MSN
Ensysce's Breakthrough Pain Drug Gets FDA Special Status; Secures $23.7M Funding Boost - StockTitan
Ensysce Biosciences (NASDAQ:ENSC) Shares Down 5.6% – Should You Sell? - Defense World
Ensysce Biosciences Regains Full Compliance with Nasdaq - Financial Content
Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection Drug Development - StockTitan
983,518 Shares in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Bought by Anson Funds Management LP - MarketBeat
ENSC Stock Touches 52-Week High at $7.24 Amid Market Volatility - Investing.com Nigeria
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study - Marketscreener.com
Revolutionizing Pain Relief: The next generation of opioids | Interview with Ensysce Biosciences CEO - Marketscreener.com
Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study - Marketscreener.com
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic - Marketscreener.com
Ensysce Biosciences, Inc. Submits Phase 3 Protocol to the FDA - Marketscreener.com
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR - Marketscreener.com
Ensysce Biosciences, Inc. Announces Strategic Partnership for the Development and Commercial Launch of Pf614 and Pf614-Mpar - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Renewal of Collaboration with Quotient Sciences to Undertake the Study PF614-MPAR-102 to Examine and Evaluate the Full Commercial Dose Range of the PF614-MPAR Drug Product - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ensysce Biosciences Lands $10M Strategic Manufacturing Deal for Novel Pain Relief Pipeline - StockTitan
Ensysce Biosciences announces reverse stock split By Investing.com - Investing.com UK
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing - StockTitan
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 - Marketscreener.com
Ensysce Biosciences Launches Key Trial for Breakthrough Opioid Drug, Backed by $14M NIDA Grant | ENSC Stock News - StockTitan
Anson Funds Management LP Acquires New Stake in Ensysce Bioscien - GuruFocus.com
Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate - Simply Wall St
Comparing Ensysce Biosciences (NASDAQ:ENSC) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Defense World
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):